{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T22:14:09Z","timestamp":1790374449359,"version":"4.1.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2019,3,28]],"date-time":"2019-03-28T00:00:00Z","timestamp":1553731200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,2,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The concurrent treatment of tuberculosis and human immunodeficiency virus (HIV) is challenging, owing to drug interactions, overlapping toxicities, and immune reconstitution inflammatory syndrome (IRIS). The efficacy and safety of dolutegravir (DTG) were assessed in adults with HIV and drug-susceptible tuberculosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>International Study of Patients with HIV on Rifampicin ING is a noncomparative, active-control, randomized, open-label study in HIV-1\u2013infected antiretroviral therapy\u2013naive adults (CD4+ \u226550 cells\/mm3). Participants on rifampicin-based tuberculosis treatment \u22648 weeks were randomized (3:2) to receive DTG (50 mg twice daily both during and 2 weeks after tuberculosis therapy, then 50 mg once daily) or efavirenz (EFV; 600 mg daily) with 2 nucleoside reverse transcriptase inhibitors for 52 weeks. The primary endpoint was the proportion of DTG-arm participants with plasma HIV-1-RNA &amp;lt;50 copies\/mL (responders) by the Food and Drug Administration Snapshot algorithm (intent-to-treat exposed population) at Week 48. The study was not powered to compare arms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>For DTG (n = 69), the baseline HIV-1 RNA was &amp;gt;100 000 copies\/mL in 64% of participants, with a median CD4+ count of 208 cells\/mm3; for EFV (n = 44), 55% of participants had HIV-1 RNA &amp;gt;100 000 copies\/mL, with a median CD4+ count of 202 cells\/mm3. The Week 48 response rates were 75% (52\/69, 95% confidence interval [CI] 65\u201386%) for DTG and 82% (36\/44, 95% CI 70\u201393%) for EFV. The DTG nonresponses were driven by non\u2013treatment related discontinuations (n = 10 lost to follow-up). There were no deaths or study drug switches. There were 2 discontinuations for toxicity (EFV). There were 3 protocol-defined virological failures (2 DTG, no acquired resistance; 1 EFV, emergent resistance to nucleoside reverse transcriptase inhibitors and nonnucleoside reverse transcriptase inhibitors). The tuberculosis treatment success rate was high. Tuberculosis-associated IRIS was uncommon (4\/arm), with no discontinuations for IRIS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Among adults with HIV receiving rifampicin-based tuberculosis treatment, twice-daily DTG was effective and well tolerated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trials Registration<\/jats:title>\n                    <jats:p>NCT02178592.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciz256","type":"journal-article","created":{"date-parts":[[2019,3,25]],"date-time":"2019-03-25T16:22:43Z","timestamp":1553530963000},"page":"549-556","source":"Crossref","is-referenced-by-count":71,"title":["Dolutegravir-based Antiretroviral Therapy for Patients Coinfected With Tuberculosis and Human Immunodeficiency Virus: A Multicenter, Noncomparative, Open-label, Randomized Trial"],"prefix":"10.1093","volume":"70","author":[{"given":"Kelly E","family":"Dooley","sequence":"first","affiliation":[{"name":"Center for Tuberculosis Research, Johns Hopkins University School of Medicine , Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Kaplan","sequence":"additional","affiliation":[{"name":"Desmond Tutu Human Immunodeficiency Virus (HIV) Foundation , Cape Town"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noluthando","family":"Mwelase","sequence":"additional","affiliation":[{"name":"Clinical HIV Research Unit , Johannesburg,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Grinsztejn","sequence":"additional","affiliation":[{"name":"Instituto de Pesquisa Cl\u00ednica Evandro Chagas Funda\u00e7\u00e3o Oswaldo Cruz (Fiocruz) , Rio de Janeiro,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Ticona","sequence":"additional","affiliation":[{"name":"Hospital Nacional Dos de Mayo, Universidad Nacional Mayor de San Marcos , Lima,","place":["Peru"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Lacerda","sequence":"additional","affiliation":[{"name":"Instituto Le\u00f4nidas & Maria Deane (Fiocruz)\/Tropical Medicine Foundation Dr Heitor Vieira Dourado , Manaus,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Sued","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n Hu\u00e9sped , Buenos Aires,","place":["Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Belonosova","sequence":"additional","affiliation":[{"name":"Regional Center For Prevention and Treatment of Acquired Immunodeficiency Syndrome and Infectious Diseases , Orel,","place":["Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mounir","family":"Ait-Khaled","sequence":"additional","affiliation":[{"name":"ViiV Healthcare Ltd. , Brentford"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Angelis","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline , Uxbridge,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dannae","family":"Brown","sequence":"additional","affiliation":[{"name":"ViiV Healthcare Ltd. , Melbourne, Victoria,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajendra","family":"Singh","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline , Collegeville, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine L","family":"Talarico","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Research Triangle Park, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan R","family":"Tenorio","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Research Triangle Park, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R","family":"Keegan","sequence":"additional","affiliation":[{"name":"ViiV Healthcare Ltd. , Brentford"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Aboud","sequence":"additional","affiliation":[{"name":"ViiV Healthcare Ltd. , Brentford"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"International Study of Patients with HIV on Rifampicin ING study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly E","family":"Dooley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaplan","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mwelase","family":"Noluthando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grinsztejn","family":"Beatriz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ticona Chavez","family":"Eduardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lacerda","family":"Marcus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sued","family":"Omar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belonosova","family":"Elena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ait-Khaled","family":"Mounir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelis","family":"Konstantinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brown","family":"Dannae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Singh","family":"Rajendra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine L","family":"Talarico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan R","family":"Tenorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R","family":"Keegan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aboud","family":"Michael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lupo","family":"Sergio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cahn","family":"Pedro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Porteiro","family":"Norma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Lopardo","family":"Gustavo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riegel Santos","family":"Breno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madruga","family":"Jose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto Alves","family":"Carlos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia Quintero Perez","family":"Nora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodriguez Noriega","family":"Eduardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perez Rios","family":"Alma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perez Patrigeon","family":"Santiago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mosqueda-G\u00f3mez","family":"Juan-Luis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paredes Paredes","family":"Mercedes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodriguez","family":"Aldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mac Rae","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casapia","family":"Wilfredo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanchez Vergaray","family":"Eduardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belonosova","family":"Elena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sultanov","family":"Lenar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivanova","family":"Elvira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yakovlev","family":"Alexey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panteleev","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawson","family":"Rodney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Latiff","family":"Gulam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohapi","family":"Lerato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taljaard","family":"Jantjie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurgens Lombaard","family":"Johannes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khan","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Variava","family":"Ebrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chetchotisakd","family":"Ploenchan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiertiburanakul","family":"Sasisopin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avihingsanon","family":"Anchalee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,3,28]]},"reference":[{"key":"2024111411405967700_CIT0001","volume-title":"Global tuberculosis report 2018","author":"World Health Organization","year":"2018"},{"key":"2024111411405967700_CIT0002","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1056\/NEJMoa1013607","article-title":"Timing of antiretroviral therapy for HIV-1 infection and tuberculosis","volume":"365","author":"Havlir","year":"2011","journal-title":"N Engl J Med"},{"key":"2024111411405967700_CIT0003","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJMoa1013911","article-title":"Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis","volume":"365","author":"Blanc","year":"2011","journal-title":"N Engl J Med"},{"key":"2024111411405967700_CIT0004","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1056\/NEJMoa1014181","article-title":"Integration of antiretroviral therapy with tuberculosis treatment","volume":"365","author":"Abdool Karim","year":"2011","journal-title":"N Engl J Med"},{"key":"2024111411405967700_CIT0005","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1056\/NEJMoa0905848","article-title":"Timing of initiation of antiretroviral drugs during tuberculosis therapy","volume":"362","author":"Abdool Karim","year":"2010","journal-title":"N Engl J Med"},{"key":"2024111411405967700_CIT0006","volume-title":"Guidelines for treatment of drug-susceptible tuberculosis and patient care: 2017 update","author":"World Health Organization","year":"2017"},{"key":"2024111411405967700_CIT0007","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1086\/518655","article-title":"Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome","volume":"196","author":"McIlleron","year":"2007","journal-title":"J Infect Dis"},{"key":"2024111411405967700_CIT0008","first-page":"367","article-title":"Experimental models to explain the high sterilizing activity of rifampin in the chemotherapy of tuberculosis","volume":"123","author":"Dickinson","year":"1981","journal-title":"Am Rev Respir Dis"},{"key":"2024111411405967700_CIT0009","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/clinids\/5.Supplement_3.S407","article-title":"Rifampin: mechanisms of action and resistance","volume":"5","author":"Wehrli","year":"1983","journal-title":"Rev Infect Dis"},{"key":"2024111411405967700_CIT0010","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1086\/591459","article-title":"Drug interactions involving combination antiretroviral therapy and other anti-infective agents: repercussions for resource-limited countries","volume":"198","author":"Dooley","year":"2008","journal-title":"J Infect Dis"},{"key":"2024111411405967700_CIT0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1185\/03007995.2012.747952","article-title":"Update on rifampin, rifabutin, and rifapentine drug interactions","volume":"29","author":"Baciewicz","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"2024111411405967700_CIT0012","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s40262-013-0093-2","article-title":"Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir","volume":"52","author":"Cottrell","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"2024111411405967700_CIT0013","article-title":"Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects","author":"Dooley","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2024111411405967700_CIT0014","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S1473-3099(13)70007-0","article-title":"Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial","volume":"13","author":"Bonnet","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"2024111411405967700_CIT0015","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12981-016-0106-y","article-title":"Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial","volume":"13","author":"Manosuthi","year":"2016","journal-title":"AIDS Res Ther"},{"key":"2024111411405967700_CIT0016","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1473-3099(14)70711-X","article-title":"Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial","volume":"14","author":"Grinsztejn","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"2024111411405967700_CIT0017","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1111\/bcp.13600","article-title":"Pharmacokinetics of efavirenz in patients on antituberculosis treatment in high human immunodeficiency virus and tuberculosis burden countries: a systematic review","volume":"84","author":"Atwine","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"2024111411405967700_CIT0018","first-page":"101","article-title":"Drug interactions with cobicistat- or ritonavir-boosted elvitegravir","volume":"18","author":"Nguyen","year":"2016","journal-title":"AIDS Rev"},{"key":"2024111411405967700_CIT0019","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1093\/jac\/dku348","article-title":"Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationship","volume":"70","author":"Bhatt","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2024111411405967700_CIT0020","first-page":"409","article-title":"CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions\u2014review of the literature","volume":"12","author":"Emmelkamp","year":"2007","journal-title":"Eur J Med Res"},{"key":"2024111411405967700_CIT0021","doi-asserted-by":"crossref","first-page":"e32173","DOI":"10.1371\/journal.pone.0032173","article-title":"The safety, effectiveness and concentrations of adjusted lopinavir\/ritonavir in HIV-infected adults on rifampicin-based antitubercular therapy","volume":"7","author":"Decloedt","year":"2012","journal-title":"PLOS One"},{"key":"2024111411405967700_CIT0022","article-title":"Pharmacokinetics of bictegravir administered twice daily in combination with rifampin","author":"Custodio","year":"2018","journal-title":"Conf Retrovir Oppor Infect"},{"key":"2024111411405967700_CIT0023","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S1473-3099(11)70290-0","article-title":"Once daily dolutegravir (S\/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial","volume":"12","author":"van Lunzen","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"2024111411405967700_CIT0024","first-page":"405","article-title":"Integrase strand transfer inhibitors and the emergence of Immune Reconstitution Inflammatory Syndrome (IRIS)","volume":"15","author":"Psichogiou","year":"2017","journal-title":"Curr HIV Res"},{"key":"2024111411405967700_CIT0025","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/COH.0000000000000445","article-title":"Risks of cardiovascular or central nervous system adverse events and immune reconstitution inflammatory syndrome, for dolutegravir versus other antiretrovirals: meta-analysis of randomized trials","volume":"13","author":"Hill","year":"2018","journal-title":"Curr Opin HIV AIDS"},{"key":"2024111411405967700_CIT0026","unstructured":"Gibb\n              D\n            , SzubertAJ, ChidzivaE, et al.\n          Impact of raltegravir intensification of first-line ART on IRIS in the REALITY trial. In: Proceedings and abstracts of the Conference on Retroviruses and Opportunistic Infections (Boston, MA).2018."},{"key":"2024111411405967700_CIT0027","volume-title":"Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection","author":"World Health Organization","year":"2016"},{"key":"2024111411405967700_CIT0028","article-title":"Update on antiretroviral regimens for treating and preventing HIV infection and update on early infant diagnosis of HIV","author":"World Health Organization","year":"2018"},{"key":"2024111411405967700_CIT0029","volume-title":"HIV drug resistance report 2017","author":"World Health Organization","year":"2017"},{"key":"2024111411405967700_CIT0030","first-page":"S807","article-title":"Expansion of viral load testing and the potential impact on HIV drug resistance","volume":"216","author":"Raizes","year":"2017","journal-title":"J Infect Dis"},{"key":"2024111411405967700_CIT0031","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1186\/s12879-017-2864-0","article-title":"Nevirapine- versus Efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and Tuberculosis infections in India: a multi-centre study","volume":"17","author":"Sinha","year":"2017","journal-title":"BMC Infect Dis"},{"key":"2024111411405967700_CIT0032","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1086\/599114","article-title":"A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study","volume":"48","author":"Manosuthi","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2024111411405967700_CIT0033","volume-title":"Pharmacokinetics of dolutegravir 100 mg once-daily with rifampicin","author":"Wang","year":"2018"},{"key":"2024111411405967700_CIT0034","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1080\/14656566.2017.1309023","article-title":"Antiretroviral treatment in HIV-infected children who require a rifamycin-containing regimen for tuberculosis","volume":"18","author":"Rabie","year":"2017","journal-title":"Expert Opin Pharmacother"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciz256\/28847904\/ciz256.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/70\/4\/549\/32312697\/ciz256.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/70\/4\/549\/32312697\/ciz256.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T07:20:45Z","timestamp":1731568845000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/70\/4\/549\/5421214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,28]]},"references-count":34,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,3,28]]},"published-print":{"date-parts":[[2020,2,3]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciz256","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,2,15]]},"published":{"date-parts":[[2019,3,28]]}}}